In addition, we were inspired by a recent preclinical discovery, demonstrating that sorafenib improved the efficacy of anti‐PD‐1 antibody in a murine BNL‐MEA HCC model, in which immune checkpoint inhibitor treatment yielded minimal benefit alone.[5] Anti‐angiogenic drugs can significantly improve the tumor microenvironment and facilitate the effects of PD‐1/PD‐L1 monoclonal antibodies. This evidence concerns the gene CD274 and hepatocellular carcinoma.